Loading...
•
Mar 31, 2023
Mink Therapeutics Q1 2023 Earnings Report
Reported corporate update and financial results for the first quarter 2023.
Key Takeaways
MiNK Therapeutics reported its Q1 2023 financial results, with a net loss of $5.7 million, or $0.17 per share. The company ended the quarter with a cash balance of $14.9 million. AgenT-797 has shown pioneering data in advanced solid cancers and expansion studies have launched in anti-PD-1 refractory NSCLC and gastric cancer.
Cash balance of $14.9 million as of the end of Q1 2023.
Cash used in operations for the quarter ended March 31, 2023, was $4.4 million.
Net loss for the quarter ended March 31, 2023, was $5.7 million or $0.17 per share.
AgenT-797 showed clinical benefit and tolerable safety across a range of heavily pre-treated solid tumor cancers.